Oligosarcomas, IDH-mutant are distinct and aggressive
Oligodendrogliomas are defined at the molecular level by the presence of an IDH mutation and codeletion of chromosomal arms 1p and 19q. In the past, case reports and small studies described gliomas with sarcomatous features arising from oligodendrogliomas, so called oligosarcomas. Here, we report a...
Saved in:
| Published in | Acta neuropathologica Vol. 143; no. 2; pp. 263 - 281 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.02.2022
Springer Springer Nature B.V Springer Verlag |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0001-6322 1432-0533 1432-0533 |
| DOI | 10.1007/s00401-021-02395-z |
Cover
| Abstract | Oligodendrogliomas are defined at the molecular level by the presence of an IDH mutation and codeletion of chromosomal arms 1p and 19q. In the past, case reports and small studies described gliomas with sarcomatous features arising from oligodendrogliomas, so called oligosarcomas. Here, we report a series of 24 IDH-mutant oligosarcomas from 23 patients forming a distinct methylation class. The tumors were recurrences from prior oligodendrogliomas or developed de novo. Precursor tumors of 12 oligosarcomas were histologically and molecularly indistinguishable from conventional oligodendrogliomas. Oligosarcoma tumor cells were embedded in a dense network of reticulin fibers, frequently showing p53 accumulation, positivity for SMA and CALD1, loss of OLIG2 and gain of H3K27 trimethylation (H3K27me3) as compared to primary lesions. In 5 oligosarcomas no 1p/19q codeletion was detectable, although it was present in the primary lesions. Copy number neutral LOH was determined as underlying mechanism. Oligosarcomas harbored an increased chromosomal copy number variation load with frequent
CDKN2A/B
deletions. Proteomic profiling demonstrated oligosarcomas to be highly distinct from conventional CNS WHO grade 3 oligodendrogliomas with consistent evidence for a smooth muscle differentiation. Expression of several tumor suppressors was reduced with NF1 being lost frequently. In contrast, oncogenic YAP1 was aberrantly overexpressed in oligosarcomas. Panel sequencing revealed mutations in
NF1
and
TP53
along with
IDH1/2
and
TERT
promoter mutations. Survival of patients was significantly poorer for oligosarcomas as first recurrence than for grade 3 oligodendrogliomas as first recurrence. These results establish oligosarcomas as a distinct group of IDH-mutant gliomas differing from conventional oligodendrogliomas on the histologic, epigenetic, proteomic, molecular and clinical level. The diagnosis can be based on the combined presence of (a) sarcomatous histology, (b) IDH-mutation and (c)
TERT
promoter mutation and/or 1p/19q codeletion, or, in unresolved cases, on its characteristic DNA methylation profile. |
|---|---|
| AbstractList | Oligodendrogliomas are defined at the molecular level by the presence of an IDH mutation and codeletion of chromosomal arms 1p and 19q. In the past, case reports and small studies described gliomas with sarcomatous features arising from oligodendrogliomas, so called oligosarcomas. Here, we report a series of 24 IDH-mutant oligosarcomas from 23 patients forming a distinct methylation class. The tumors were recurrences from prior oligodendrogliomas or developed de novo. Precursor tumors of 12 oligosarcomas were histologically and molecularly indistinguishable from conventional oligodendrogliomas. Oligosarcoma tumor cells were embedded in a dense network of reticulin fibers, frequently showing p53 accumulation, positivity for SMA and CALD1, loss of OLIG2 and gain of H3K27 trimethylation (H3K27me3) as compared to primary lesions. In 5 oligosarcomas no 1p/19q codeletion was detectable, although it was present in the primary lesions. Copy number neutral LOH was determined as underlying mechanism. Oligosarcomas harbored an increased chromosomal copy number variation load with frequent
CDKN2A/B
deletions. Proteomic profiling demonstrated oligosarcomas to be highly distinct from conventional CNS WHO grade 3 oligodendrogliomas with consistent evidence for a smooth muscle differentiation. Expression of several tumor suppressors was reduced with NF1 being lost frequently. In contrast, oncogenic YAP1 was aberrantly overexpressed in oligosarcomas. Panel sequencing revealed mutations in
NF1
and
TP53
along with
IDH1/2
and
TERT
promoter mutations. Survival of patients was significantly poorer for oligosarcomas as first recurrence than for grade 3 oligodendrogliomas as first recurrence. These results establish oligosarcomas as a distinct group of IDH-mutant gliomas differing from conventional oligodendrogliomas on the histologic, epigenetic, proteomic, molecular and clinical level. The diagnosis can be based on the combined presence of (a) sarcomatous histology, (b) IDH-mutation and (c)
TERT
promoter mutation and/or 1p/19q codeletion, or, in unresolved cases, on its characteristic DNA methylation profile. Oligodendrogliomas are defined at the molecular level by the presence of an IDH mutation and codeletion of chromosomal arms 1p and 19q. In the past, case reports and small studies described gliomas with sarcomatous features arising from oligodendrogliomas, so called oligosarcomas. Here, we report a series of 24 IDH-mutant oligosarcomas from 23 patients forming a distinct methylation class. The tumors were recurrences from prior oligodendrogliomas or developed de novo. Precursor tumors of 12 oligosarcomas were histologically and molecularly indistinguishable from conventional oligodendrogliomas. Oligosarcoma tumor cells were embedded in a dense network of reticulin fibers, frequently showing p53 accumulation, positivity for SMA and CALD1, loss of OLIG2 and gain of H3K27 trimethylation (H3K27me3) as compared to primary lesions. In 5 oligosarcomas no 1p/19q codeletion was detectable, although it was present in the primary lesions. Copy number neutral LOH was determined as underlying mechanism. Oligosarcomas harbored an increased chromosomal copy number variation load with frequent CDKN2A/B deletions. Proteomic profiling demonstrated oligosarcomas to be highly distinct from conventional CNS WHO grade 3 oligodendrogliomas with consistent evidence for a smooth muscle differentiation. Expression of several tumor suppressors was reduced with NF1 being lost frequently. In contrast, oncogenic YAP1 was aberrantly overexpressed in oligosarcomas. Panel sequencing revealed mutations in NF1 and TP53 along with IDH1/2 and TERT promoter mutations. Survival of patients was significantly poorer for oligosarcomas as first recurrence than for grade 3 oligodendrogliomas as first recurrence. These results establish oligosarcomas as a distinct group of IDH-mutant gliomas differing from conventional oligodendrogliomas on the histologic, epigenetic, proteomic, molecular and clinical level. The diagnosis can be based on the combined presence of (a) sarcomatous histology, (b) IDH-mutation and (c) TERT promoter mutation and/or 1p/19q codeletion, or, in unresolved cases, on its characteristic DNA methylation profile. Oligodendrogliomas are defined at the molecular level by the presence of an IDH mutation and codeletion of chromosomal arms 1p and 19q. In the past, case reports and small studies described gliomas with sarcomatous features arising from oligodendrogliomas, so called oligosarcomas. Here, we report a series of 24 IDH-mutant oligosarcomas from 23 patients forming a distinct methylation class. The tumors were recurrences from prior oligodendrogliomas or developed de novo. Precursor tumors of 12 oligosarcomas were histologically and molecularly indistinguishable from conventional oligodendrogliomas. Oligosarcoma tumor cells were embedded in a dense network of reticulin fibers, frequently showing p53 accumulation, positivity for SMA and CALD1, loss of OLIG2 and gain of H3K27 trimethylation (H3K27me3) as compared to primary lesions. In 5 oligosarcomas no 1p/19q codeletion was detectable, although it was present in the primary lesions. Copy number neutral LOH was determined as underlying mechanism. Oligosarcomas harbored an increased chromosomal copy number variation load with frequent CDKN2A/B deletions. Proteomic profiling demonstrated oligosarcomas to be highly distinct from conventional CNS WHO grade 3 oligodendrogliomas with consistent evidence for a smooth muscle differentiation. Expression of several tumor suppressors was reduced with NF1 being lost frequently. In contrast, oncogenic YAP1 was aberrantly overexpressed in oligosarcomas. Panel sequencing revealed mutations in NF1 and TP53 along with IDH1/2 and TERT promoter mutations. Survival of patients was significantly poorer for oligosarcomas as first recurrence than for grade 3 oligodendrogliomas as first recurrence. These results establish oligosarcomas as a distinct group of IDH-mutant gliomas differing from conventional oligodendrogliomas on the histologic, epigenetic, proteomic, molecular and clinical level. The diagnosis can be based on the combined presence of (a) sarcomatous histology, (b) IDH-mutation and (c) TERT promoter mutation and/or 1p/19q codeletion, or, in unresolved cases, on its characteristic DNA methylation profile. Oligodendrogliomas are defined at the molecular level by the presence of an IDH mutation and codeletion of chromosomal arms 1p and 19q. In the past, case reports and small studies described gliomas with sarcomatous features arising from oligodendrogliomas, so called oligosarcomas. Here, we report a series of 24 IDH-mutant oligosarcomas from 23 patients forming a distinct methylation class. The tumors were recurrences from prior oligodendrogliomas or developed de novo. Precursor tumors of 12 oligosarcomas were histologically and molecularly indistinguishable from conventional oligodendrogliomas. Oligosarcoma tumor cells were embedded in a dense network of reticulin fibers, frequently showing p53 accumulation, positivity for SMA and CALD1, loss of OLIG2 and gain of H3K27 trimethylation (H3K27me3) as compared to primary lesions. In 5 oligosarcomas no 1p/19q codeletion was detectable, although it was present in the primary lesions. Copy number neutral LOH was determined as underlying mechanism. Oligosarcomas harbored an increased chromosomal copy number variation load with frequent CDKN2A/B deletions. Proteomic profiling demonstrated oligosarcomas to be highly distinct from conventional CNS WHO grade 3 oligodendrogliomas with consistent evidence for a smooth muscle differentiation. Expression of several tumor suppressors was reduced with NF1 being lost frequently. In contrast, oncogenic YAP1 was aberrantly overexpressed in oligosarcomas. Panel sequencing revealed mutations in NF1 and TP53 along with IDH1/2 and TERT promoter mutations. Survival of patients was significantly poorer for oligosarcomas as first recurrence than for grade 3 oligodendrogliomas as first recurrence. These results establish oligosarcomas as a distinct group of IDH-mutant gliomas differing from conventional oligodendrogliomas on the histologic, epigenetic, proteomic, molecular and clinical level. The diagnosis can be based on the combined presence of (a) sarcomatous histology, (b) IDH-mutation and (c) TERT promoter mutation and/or 1p/19q codeletion, or, in unresolved cases, on its characteristic DNA methylation profile.Oligodendrogliomas are defined at the molecular level by the presence of an IDH mutation and codeletion of chromosomal arms 1p and 19q. In the past, case reports and small studies described gliomas with sarcomatous features arising from oligodendrogliomas, so called oligosarcomas. Here, we report a series of 24 IDH-mutant oligosarcomas from 23 patients forming a distinct methylation class. The tumors were recurrences from prior oligodendrogliomas or developed de novo. Precursor tumors of 12 oligosarcomas were histologically and molecularly indistinguishable from conventional oligodendrogliomas. Oligosarcoma tumor cells were embedded in a dense network of reticulin fibers, frequently showing p53 accumulation, positivity for SMA and CALD1, loss of OLIG2 and gain of H3K27 trimethylation (H3K27me3) as compared to primary lesions. In 5 oligosarcomas no 1p/19q codeletion was detectable, although it was present in the primary lesions. Copy number neutral LOH was determined as underlying mechanism. Oligosarcomas harbored an increased chromosomal copy number variation load with frequent CDKN2A/B deletions. Proteomic profiling demonstrated oligosarcomas to be highly distinct from conventional CNS WHO grade 3 oligodendrogliomas with consistent evidence for a smooth muscle differentiation. Expression of several tumor suppressors was reduced with NF1 being lost frequently. In contrast, oncogenic YAP1 was aberrantly overexpressed in oligosarcomas. Panel sequencing revealed mutations in NF1 and TP53 along with IDH1/2 and TERT promoter mutations. Survival of patients was significantly poorer for oligosarcomas as first recurrence than for grade 3 oligodendrogliomas as first recurrence. These results establish oligosarcomas as a distinct group of IDH-mutant gliomas differing from conventional oligodendrogliomas on the histologic, epigenetic, proteomic, molecular and clinical level. The diagnosis can be based on the combined presence of (a) sarcomatous histology, (b) IDH-mutation and (c) TERT promoter mutation and/or 1p/19q codeletion, or, in unresolved cases, on its characteristic DNA methylation profile. |
| Audience | Academic |
| Author | Wesseling, Pieter Hinz, Felix Shimizu, Hiroaki Schweizer, Leonille Schucht, Philippe Prinz, Marco Sahm, Felix Stichel, Damian Friedel, Dennis Schrimpf, Daniel Turner, Clinton Koelsche, Christian Wick, Wolfgang Reuss, David E. Korshunov, Andrey Dohmen, Hildegard Hewer, Ekkehard Pohl, Ute Felix, Marius Staszewski, Ori Cheunsuacchon, Pornsuk Le Rhun, Emilie Acker, Till Herold-Mende, Christel Stein, Marco Hartmann, Christian von Deimling, Andreas Özduman, Koray Sathornsumetee, Sith Suwala, Abigail K. Wongsurawat, Thidathip Mühlebner, Angelika Kessler, Tobias Capper, David Ono, Takahiro |
| Author_xml | – sequence: 1 givenname: Abigail K. surname: Suwala fullname: Suwala, Abigail K. organization: Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Department of Neurological Surgery, Helen Diller Research Center, University of California San Francisco – sequence: 2 givenname: Marius surname: Felix fullname: Felix, Marius organization: Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK) – sequence: 3 givenname: Dennis surname: Friedel fullname: Friedel, Dennis organization: Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK) – sequence: 4 givenname: Damian surname: Stichel fullname: Stichel, Damian organization: Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK) – sequence: 5 givenname: Daniel surname: Schrimpf fullname: Schrimpf, Daniel organization: Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK) – sequence: 6 givenname: Felix surname: Hinz fullname: Hinz, Felix organization: Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK) – sequence: 7 givenname: Ekkehard surname: Hewer fullname: Hewer, Ekkehard organization: Institute of Pathology, Lausanne University Hospital and University of Lausanne – sequence: 8 givenname: Leonille surname: Schweizer fullname: Schweizer, Leonille organization: Department of Neuropathology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ) – sequence: 9 givenname: Hildegard surname: Dohmen fullname: Dohmen, Hildegard organization: Institute of Neuropathology, University of Giessen – sequence: 10 givenname: Ute surname: Pohl fullname: Pohl, Ute organization: Department of Cellular Pathology, Queen Elizabeth Hospital/University Hospitals Birmingham – sequence: 11 givenname: Ori surname: Staszewski fullname: Staszewski, Ori organization: Institute of Neuropathology, Faculty of Medicine, University of Freiburg – sequence: 12 givenname: Andrey surname: Korshunov fullname: Korshunov, Andrey organization: Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK) – sequence: 13 givenname: Marco surname: Stein fullname: Stein, Marco organization: Department of Neurosurgery, University Hospital Gießen – sequence: 14 givenname: Thidathip surname: Wongsurawat fullname: Wongsurawat, Thidathip organization: Faculty of Medicine Siriraj Hospital, Mahidol University – sequence: 15 givenname: Pornsuk surname: Cheunsuacchon fullname: Cheunsuacchon, Pornsuk organization: Faculty of Medicine Siriraj Hospital, Mahidol University – sequence: 16 givenname: Sith surname: Sathornsumetee fullname: Sathornsumetee, Sith organization: Faculty of Medicine Siriraj Hospital, Mahidol University – sequence: 17 givenname: Christian surname: Koelsche fullname: Koelsche, Christian organization: Institute of Pathology, University Hospital Heidelberg – sequence: 18 givenname: Clinton surname: Turner fullname: Turner, Clinton organization: Centre for Brain Research, Department of Anatomy and Medical Imaging, Faculty of Medical and Health Sciences, University of Auckland, Department of Anatomical Pathology, LabPlus, Auckland City Hospital – sequence: 19 givenname: Emilie surname: Le Rhun fullname: Le Rhun, Emilie organization: Department of Neurology and Brain Tumor Center, University Hospital, University of Zurich, Department of Neurosurgery, University Hospital, University of Zurich – sequence: 20 givenname: Angelika surname: Mühlebner fullname: Mühlebner, Angelika organization: Department of Neuro Pathology, Amsterdam UMC, Location AMC, University of Amsterdam – sequence: 21 givenname: Philippe surname: Schucht fullname: Schucht, Philippe organization: Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern – sequence: 22 givenname: Koray surname: Özduman fullname: Özduman, Koray organization: Department of Neurosurgery, Acıbadem University, School of Medicine – sequence: 23 givenname: Takahiro surname: Ono fullname: Ono, Takahiro organization: Department of Neurosurgery, Akita University Graduate School of Medicine – sequence: 24 givenname: Hiroaki surname: Shimizu fullname: Shimizu, Hiroaki organization: Department of Neurosurgery, Akita University Graduate School of Medicine – sequence: 25 givenname: Marco surname: Prinz fullname: Prinz, Marco organization: Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Centre for NeuroModulation (NeuroModBasics), University of Freiburg, Signalling Research Centres BIOSS and CIBSS, University of Freiburg – sequence: 26 givenname: Till surname: Acker fullname: Acker, Till organization: Institute of Neuropathology, University of Giessen – sequence: 27 givenname: Christel surname: Herold-Mende fullname: Herold-Mende, Christel organization: Department of Neurosurgery, University Hospital Heidelberg – sequence: 28 givenname: Tobias surname: Kessler fullname: Kessler, Tobias organization: Clinical Cooperation Unit Neurooncology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital – sequence: 29 givenname: Wolfgang surname: Wick fullname: Wick, Wolfgang organization: Clinical Cooperation Unit Neurooncology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital – sequence: 30 givenname: David surname: Capper fullname: Capper, David organization: Department of Neuropathology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ) – sequence: 31 givenname: Pieter surname: Wesseling fullname: Wesseling, Pieter organization: Laboratory for Childhood Cancer Pathology, Princess Máxima Center for Pediatric Oncology, Department of Pathology, Amsterdam University Medical Centers/VUmc and Brain Tumor Center Amsterdam – sequence: 32 givenname: Felix surname: Sahm fullname: Sahm, Felix organization: Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Hopp Children’s Cancer Center (KiTZ) – sequence: 33 givenname: Andreas surname: von Deimling fullname: von Deimling, Andreas organization: Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK) – sequence: 34 givenname: Christian surname: Hartmann fullname: Hartmann, Christian email: hartmann.christian@mh-hannover.de organization: Department of Neuropathology, Institute of Pathology, Hannover Medical School (MHH) – sequence: 35 givenname: David E. orcidid: 0000-0002-4573-6033 surname: Reuss fullname: Reuss, David E. email: david.reuss@med.uni-heidelberg.de organization: Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34967922$$D View this record in MEDLINE/PubMed https://hal.univ-lille.fr/hal-04019239$$DView record in HAL |
| BookMark | eNp9kl1rFDEYhYNU7Hb1D3ghC94oODXfmdwIS61uYaE3eh0ySXaaMpPUZGbB_nozndbaRZohhDd5zpmZk_cEHIUYHABvETxFEIrPGUIKUQXxNIlk1e0LsECU4AoyQo7AAsJyzAnGx-Ak5-tSYUHZK3BMqORCYrwA7LLzbcw6mdjr_Gl18XVT9eOgw7DSya2sz4MPphTBrnTbJpez37vX4OVOd9m9uV-X4Oe38x9nm2p7-f3ibL2tDEdyqIQjjRAcOmskktZKyBsstNEEEi1tUzeOSSmoNZZSwgiHurYYmTIYa1xNluDL7HszNn1xcWFIulM3yfc6_VZRe_X0JPgr1ca9qgXFNRLF4ONscHUg26y3atqbEpQlvD0q7If7l6X4a3R5UL3PxnWdDi6OWWGOGBUMlYSX4P0Beh3HFEoUEyVqSRGDj1SrO6d82MXyjWYyVWteSwQ5Z6xQp_-hymNd70258Z0v-08E7_4N5e9vPVxqAeoZMCnmnNxOGT_owccpI98pBNXUP2ruH1X6R931j7otUnwgfXB_VkRmUS5waF16TOMZ1R-1WNUV |
| CitedBy_id | crossref_primary_10_1186_s40478_023_01520_1 crossref_primary_10_1097_CCO_0000000000000903 crossref_primary_10_4103_glioma_glioma_31_22 crossref_primary_10_3390_cancers14225679 crossref_primary_10_1007_s10014_025_00497_0 crossref_primary_10_1016_j_wneu_2024_01_120 crossref_primary_10_1186_s12951_024_02895_6 crossref_primary_10_1093_noajnl_vdae228 crossref_primary_10_1007_s11060_023_04250_5 crossref_primary_10_1093_neuonc_noac111 crossref_primary_10_1097_PAS_0000000000002118 crossref_primary_10_1007_s12033_024_01223_5 crossref_primary_10_1016_j_wneu_2024_03_028 crossref_primary_10_1177_10668969241291891 crossref_primary_10_1038_s41572_024_00516_y crossref_primary_10_1186_s40478_024_01908_7 crossref_primary_10_1016_j_pathol_2024_11_004 crossref_primary_10_1007_s00401_024_02715_z crossref_primary_10_1007_s00401_022_02529_x crossref_primary_10_1007_s00401_024_02811_0 crossref_primary_10_1016_j_xcrm_2022_100877 crossref_primary_10_1002_gcc_23041 crossref_primary_10_1038_s41368_022_00190_4 crossref_primary_10_1111_bpa_13203 crossref_primary_10_1093_neuonc_noae107 crossref_primary_10_1007_s10014_022_00446_1 crossref_primary_10_1007_s00415_025_12923_6 crossref_primary_10_1093_nop_npad040 crossref_primary_10_1093_neuonc_noac207 crossref_primary_10_1007_s00401_025_02849_8 |
| Cites_doi | 10.1007/s00401-014-1326-7 10.1056/NEJMoa1500925 10.1093/neuonc/noz016 10.1093/neuonc/noz098 10.5414/NP300577 10.1093/neuonc/not092 10.1007/s00401-019-02096-8 10.1007/s00401-020-02243-6 10.1038/s41573-020-0070-z 10.1097/NEN.0000000000000188 10.1038/s41598-019-56247-8 10.1200/JCO.2017.72.6737 10.1038/ng.3095 10.1111/pin.12723 10.1200/JCO.2012.43.2229 10.1158/1078-0432.CCR-20-0018 10.1007/s00401-018-1844-9 10.1016/j.cell.2013.09.034 10.1007/s00401-015-1519-8 10.1007/s00401-019-02123-8 10.1007/s00401-014-1370-3 10.1016/j.ccell.2016.05.005 10.1093/neuonc/nox132 10.1111/j.1750-3639.2009.00352.x 10.1186/gb-2009-10-11-r128 10.1097/00005072-197611000-00005 10.1186/s40478-017-0422-z 10.1007/s00401-020-02127-9 10.1007/s00401-017-1752-4 10.1038/nature26000 10.1007/s00401-019-02025-9 10.1007/s00401-014-1246-6 10.1038/nbt.1511 10.1007/s00701-020-04514-3 10.1097/01.pas.0000213378.94547.ae 10.1038/s41586-019-1775-1 10.1007/s00401-012-1016-2 10.3390/cancers11030284 10.1007/s10014-016-0268-2 10.1093/neuonc/noz124 10.1007/s00401-020-02194-y 10.1002/1097-0142(197812)42:6<2753::aid-cncr2820420634>3.0.co;2-k 10.1016/j.prp.2012.09.009 10.1093/neuonc/noab106 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 2021. The Author(s). COPYRIGHT 2022 Springer The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Attribution |
| Copyright_xml | – notice: The Author(s) 2021 – notice: 2021. The Author(s). – notice: COPYRIGHT 2022 Springer – notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Attribution |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TK 7U9 7X7 7XB 88E 88G 8AO 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ H94 K9. M0S M1P M2M PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 1XC VOOES 5PM |
| DOI | 10.1007/s00401-021-02395-z |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database (ProQuest) Psychology Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef ProQuest One Psychology MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1432-0533 |
| EndPage | 281 |
| ExternalDocumentID | PMC8742817 oai_HAL_hal_04019239v1 A689106655 34967922 10_1007_s00401_021_02395_z |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: bundesministerium für bildung und forschung grantid: 031L0212A funderid: http://dx.doi.org/10.13039/501100002347 – fundername: deutsche forschungsgemeinschaft grantid: 404521405; 404521405 funderid: http://dx.doi.org/10.13039/501100001659 – fundername: deutsche krebshilfe grantid: 70112188 funderid: http://dx.doi.org/10.13039/501100005972 – fundername: niedersächsischen krebsgesellschaft funderid: http://dx.doi.org/10.13039/501100011835 – fundername: Universitätsklinikum Heidelberg (8914) – fundername: ; – fundername: ; grantid: 031L0212A – fundername: ; grantid: 404521405; 404521405 – fundername: ; grantid: 70112188 |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .55 .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 23M 28- 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 78A 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABIVO ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFEXP AFFNX AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN AZQEC B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI C6C CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DWQXO EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO IHE IHR IJ- IKXTQ IMOTQ INH INR IPY ITC ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH L7B LAS LLZTM M1P M2M M4Y MA- N2Q NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PSYQQ PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WJK WK8 X7M YLTOR Z45 Z7U Z7V Z81 Z82 Z83 Z87 Z8O Z8P Z8U Z8V Z8W Z91 ZGI ZOVNA ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM AEIIB PMFND 7TK 7U9 7XB 8FK ABRTQ H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS PUEGO Q9U 7X8 1XC VOOES 5PM |
| ID | FETCH-LOGICAL-c619t-7e3b7760edc919dd906b27aca303a9db8be59974dcd4435360a8d21cccc55be83 |
| IEDL.DBID | 7X7 |
| ISSN | 0001-6322 1432-0533 |
| IngestDate | Thu Aug 21 13:37:41 EDT 2025 Fri Sep 12 12:48:33 EDT 2025 Fri Sep 05 11:47:36 EDT 2025 Sun Sep 07 05:41:02 EDT 2025 Tue Jun 17 22:10:39 EDT 2025 Tue Jun 10 21:03:49 EDT 2025 Wed Feb 19 02:27:18 EST 2025 Tue Jul 01 03:38:19 EDT 2025 Thu Apr 24 23:13:08 EDT 2025 Fri Feb 21 02:46:29 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | YAP1 Prognosis 1p/19q SMA Oligosarcoma Oligodendroglioma Variant Type TERT NF1 DNA methylation Codeletion Gliosarcoma TP53 Subtype 19q 1p |
| Language | English |
| License | 2021. The Author(s). Attribution: http://creativecommons.org/licenses/by Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c619t-7e3b7760edc919dd906b27aca303a9db8be59974dcd4435360a8d21cccc55be83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-4573-6033 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://link.springer.com/10.1007/s00401-021-02395-z |
| PMID | 34967922 |
| PQID | 2617894150 |
| PQPubID | 49178 |
| PageCount | 19 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8742817 hal_primary_oai_HAL_hal_04019239v1 proquest_miscellaneous_2615475114 proquest_journals_2617894150 gale_infotracmisc_A689106655 gale_infotracacademiconefile_A689106655 pubmed_primary_34967922 crossref_citationtrail_10_1007_s00401_021_02395_z crossref_primary_10_1007_s00401_021_02395_z springer_journals_10_1007_s00401_021_02395_z |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-02-01 |
| PublicationDateYYYYMMDD | 2022-02-01 |
| PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationSubtitle | Pathology and Mechanisms of Neurological Disease |
| PublicationTitle | Acta neuropathologica |
| PublicationTitleAbbrev | Acta Neuropathol |
| PublicationTitleAlternate | Acta Neuropathol |
| PublicationYear | 2022 |
| Publisher | Springer Berlin Heidelberg Springer Springer Nature B.V Springer Verlag |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer – name: Springer Nature B.V – name: Springer Verlag |
| References | Hiniker, Hagenkord, Powers, Aghi, Prados, Perry (CR19) 2013; 32 Ono, Reinhardt, Takahashi, Nanjo, Kamataki, Deimling (CR25) 2020; 162 Reuss, Sahm, Schrimpf, Wiestler, Capper, Koelsche (CR33) 2015; 129 Chen, Thomas, Munoz, Alexandrescu, Horbinski, Olar (CR13) 2019 Sahm, Schrimpf, Jones, Meyer, Kratz, Reuss (CR37) 2016; 131 Vigneswaran, Boyd, Oh, Lallani, Boucher, Neill (CR45) 2021; 27 Rodriguez, Scheithauer, Jenkins, Burger, Rudzinskiy, Vlodavsky (CR34) 2007; 31 Ren, Jiang, Cui, Cui, Ma, Jiang (CR31) 2013; 15 van den Bent, Smits, Kros, Chang (CR44) 2017; 35 Feller, Felix, Weiss, Herold-Mende, Zhang, Kockmann (CR17) 2020; 139 CR35 Shoji, Saito, Kanamori, Sonoda, Watanabe, Tominaga (CR38) 2016; 33 Feigin, Ransohoff, Lieberman (CR16) 1976; 35 Reuss, Habel, Hagenlocher, Mucha, Ackermann, Tessmer (CR32) 2014; 127 Katz, Hielscher, Liechty, Silverman, Zagzag, Sen (CR21) 2018; 135 Vajtai, Vassella, Hewer, Kappeler, Reinert (CR42) 2012; 208 Capper, Jones, Sill, Hovestadt, Schrimpf, Sturm (CR11) 2018; 555 Aihara, Mukasa, Nagae, Nomura, Yamamoto, Ueda (CR2) 2017; 5 Isfort, Elges, Cyra, Berthold, Renner, Mechtersheimer (CR20) 2019; 9 Tanaka, Hitotsumatsu, Sugita, Ishido, Ito, Hatae (CR41) 2018; 68 Appay, Dehais, Maurage, Alentorn, Carpentier, Colin (CR4) 2019; 21 Aoki, Nakamura, Suzuki, Matsuo, Kataoka, Shimamura (CR3) 2018; 20 Dey, Varelas, Guan (CR15) 2020; 19 Buckner, Shaw, Pugh, Chakravarti, Gilbert, Barger (CR10) 2016; 374 Wojtas, Gielniewski, Wojnicki, Maleszewska, Mondal, Nauman (CR46) 2019 Suwala, Stichel, Schrimpf, Kloor, Wefers, Reinhardt (CR40) 2021; 141 Pasquier, Couderc, Pasquier, Panh, N'Golet (CR27) 1978; 42 Brat, Aldape, Colman, Figrarella-Branger, Fuller, Giannini (CR8) 2020; 139 Capper, Weissert, Balss, Habel, Meyer, Jager (CR12) 2010; 20 Reis, Pekmezci, Hansen, Rice, Marshall, Molinaro (CR30) 2015; 74 Banan, Stichel, Bleck, Hong, Lehmann, Suwala (CR6) 2020; 140 Miller, Loebel, Juratli, Tummala, Williams, Batchelor (CR24) 2019; 21 Bady, Sciuscio, Diserens, Bloch, van den Bent, Marosi (CR5) 2012; 124 Brennan, Verhaak, McKenna, Campos, Noushmehr, Salama (CR9) 2013; 155 CR23 Agozzino, Pittore, Lamendola, Ambrosio (CR1) 1983; 75 Barthel, Johnson, Varn, Moskalik, Tanner, Kocakavuk (CR7) 2019; 576 Cox, Mann (CR14) 2008; 26 van den Bent, Brandes, Taphoorn, Kros, Kouwenhoven, Delattre (CR43) 2013; 31 Filipski, Braun, Zinke, Roller, Baumgarten, Wagner (CR18) 2019; 138 Suwala, Stichel, Schrimpf, Kloor, Wefers, Reinhardt (CR39) 2020 Lee, Teckie, Wiesner, Ran, Prieto Granada, Lin (CR22) 2014; 46 Panwalkar, Clark, Ramaswamy, Hawes, Yang, Dunham (CR26) 2017; 134 Pekmezci, Phillips, Dirilenoglu, Atasever-Rezanko, Tihan, Solomon (CR28) 2020; 139 Sahm, Reuss, Koelsche, Capper, Schittenhelm, Heim (CR36) 2014; 128 Zanconato, Cordenonsi, Piccolo (CR47) 2016; 29 Popova, Manie, Stoppa-Lyonnet, Rigaill, Barillot, Stern (CR29) 2009; 10 CW Brennan (2395_CR9) 2013; 155 GF Reis (2395_CR30) 2015; 74 K Aoki (2395_CR3) 2018; 20 R Banan (2395_CR6) 2020; 140 FJ Rodriguez (2395_CR34) 2007; 31 T Shoji (2395_CR38) 2016; 33 L Agozzino (2395_CR1) 1983; 75 W Lee (2395_CR22) 2014; 46 H Chen (2395_CR13) 2019 M Pekmezci (2395_CR28) 2020; 139 A Dey (2395_CR15) 2020; 19 J Cox (2395_CR14) 2008; 26 B Wojtas (2395_CR46) 2019 K Filipski (2395_CR18) 2019; 138 B Pasquier (2395_CR27) 1978; 42 X Ren (2395_CR31) 2013; 15 F Sahm (2395_CR37) 2016; 131 2395_CR23 MJ van den Bent (2395_CR44) 2017; 35 DE Reuss (2395_CR33) 2015; 129 JJ Miller (2395_CR24) 2019; 21 AK Suwala (2395_CR40) 2021; 141 I Vajtai (2395_CR42) 2012; 208 I Feigin (2395_CR16) 1976; 35 F Zanconato (2395_CR47) 2016; 29 I Isfort (2395_CR20) 2019; 9 S Tanaka (2395_CR41) 2018; 68 FP Barthel (2395_CR7) 2019; 576 C Feller (2395_CR17) 2020; 139 R Appay (2395_CR4) 2019; 21 K Aihara (2395_CR2) 2017; 5 T Popova (2395_CR29) 2009; 10 AK Suwala (2395_CR39) 2020 F Sahm (2395_CR36) 2014; 128 D Capper (2395_CR11) 2018; 555 MJ van den Bent (2395_CR43) 2013; 31 JC Buckner (2395_CR10) 2016; 374 K Vigneswaran (2395_CR45) 2021; 27 D Capper (2395_CR12) 2010; 20 P Panwalkar (2395_CR26) 2017; 134 DE Reuss (2395_CR32) 2014; 127 T Ono (2395_CR25) 2020; 162 LM Katz (2395_CR21) 2018; 135 P Bady (2395_CR5) 2012; 124 A Hiniker (2395_CR19) 2013; 32 2395_CR35 DJ Brat (2395_CR8) 2020; 139 |
| References_xml | – volume: 128 start-page: 551 year: 2014 end-page: 559 ident: CR36 article-title: Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma publication-title: Acta Neuropathol doi: 10.1007/s00401-014-1326-7 – volume: 374 start-page: 1344 year: 2016 end-page: 1355 ident: CR10 article-title: Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma publication-title: N Engl J Med doi: 10.1056/NEJMoa1500925 – volume: 21 start-page: 669 year: 2019 end-page: 677 ident: CR24 article-title: Accelerated progression of IDH mutant glioma after first recurrence publication-title: Neuro Oncol doi: 10.1093/neuonc/noz016 – year: 2019 ident: CR13 article-title: Polysomy is associated with poor outcome in 1p19q co-deleted oligodendroglial tumors publication-title: Neuro Oncol doi: 10.1093/neuonc/noz098 – volume: 32 start-page: 165 year: 2013 end-page: 170 ident: CR19 article-title: Gliosarcoma arising from an oligodendroglioma (oligosarcoma) publication-title: Clin Neuropathol doi: 10.5414/NP300577 – volume: 15 start-page: 1244 year: 2013 end-page: 1250 ident: CR31 article-title: Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases publication-title: Neuro Oncol doi: 10.1093/neuonc/not092 – volume: 139 start-page: 211 year: 2020 end-page: 213 ident: CR17 article-title: Histone epiproteomic profiling distinguishes oligodendroglioma, IDH-mutant and 1p/19q co-deleted from IDH-mutant astrocytoma and reveals less tri-methylation of H3K27 in oligodendrogliomas publication-title: Acta Neuropathol doi: 10.1007/s00401-019-02096-8 – volume: 141 start-page: 85 year: 2021 end-page: 100 ident: CR40 article-title: Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis publication-title: Acta Neuropathol doi: 10.1007/s00401-020-02243-6 – volume: 19 start-page: 480 year: 2020 end-page: 494 ident: CR15 article-title: Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine publication-title: Nat Rev Drug Discov doi: 10.1038/s41573-020-0070-z – ident: CR35 – volume: 74 start-page: 442 year: 2015 end-page: 452 ident: CR30 article-title: CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas publication-title: J Neuropathol Exp Neurol doi: 10.1097/NEN.0000000000000188 – volume: 9 start-page: 19704 year: 2019 ident: CR20 article-title: Prevalence of the hippo effectors YAP1/TAZ in tumors of soft tissue and bone publication-title: Sci Rep doi: 10.1038/s41598-019-56247-8 – volume: 35 start-page: 2394 year: 2017 end-page: 2401 ident: CR44 article-title: Diffuse infiltrating oligodendroglioma and astrocytoma publication-title: J Clin Oncol doi: 10.1200/JCO.2017.72.6737 – volume: 46 start-page: 1227 year: 2014 end-page: 1232 ident: CR22 article-title: PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors publication-title: Nat Genet doi: 10.1038/ng.3095 – year: 2020 ident: CR39 article-title: Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis publication-title: Acta Neuropathol doi: 10.1007/s00401-020-02243-6 – volume: 68 start-page: 567 year: 2018 end-page: 573 ident: CR41 article-title: Gliosarcoma arising from oligodendroglioma (Oligosarcoma): a case report with genetic analyses publication-title: Pathol Int doi: 10.1111/pin.12723 – volume: 31 start-page: 344 year: 2013 end-page: 350 ident: CR43 article-title: Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.43.2229 – volume: 27 start-page: 1553 year: 2021 end-page: 1569 ident: CR45 article-title: YAP/TAZ transcriptional coactivators create therapeutic vulnerability to verteporfin in EGFR-mutant glioblastoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-20-0018 – volume: 135 start-page: 955 year: 2018 end-page: 963 ident: CR21 article-title: Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence publication-title: Acta Neuropathol doi: 10.1007/s00401-018-1844-9 – ident: CR23 – volume: 155 start-page: 462 year: 2013 end-page: 477 ident: CR9 article-title: The somatic genomic landscape of glioblastoma publication-title: Cell doi: 10.1016/j.cell.2013.09.034 – volume: 131 start-page: 903 year: 2016 end-page: 910 ident: CR37 article-title: Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets publication-title: Acta Neuropathol doi: 10.1007/s00401-015-1519-8 – volume: 139 start-page: 597 year: 2020 end-page: 600 ident: CR28 article-title: Loss of H3K27 trimethylation by immunohistochemistry is frequent in oligodendroglioma, IDH-mutant and 1p/19q-codeleted, but is neither a sensitive nor a specific marker publication-title: Acta Neuropathol doi: 10.1007/s00401-019-02123-8 – volume: 75 start-page: 501 year: 1983 end-page: 508 ident: CR1 article-title: Sarcoma arising in a cerebral oligodendroglioma. Case report publication-title: Pathologica – volume: 129 start-page: 133 year: 2015 end-page: 146 ident: CR33 article-title: ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma publication-title: Acta Neuropathol doi: 10.1007/s00401-014-1370-3 – volume: 29 start-page: 783 year: 2016 end-page: 803 ident: CR47 article-title: YAP/TAZ at the roots of cancer publication-title: Cancer Cell doi: 10.1016/j.ccell.2016.05.005 – volume: 20 start-page: 66 year: 2018 end-page: 77 ident: CR3 article-title: Prognostic relevance of genetic alterations in diffuse lower-grade gliomas publication-title: Neuro Oncol doi: 10.1093/neuonc/nox132 – volume: 20 start-page: 245 year: 2010 end-page: 254 ident: CR12 article-title: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors publication-title: Brain Pathol doi: 10.1111/j.1750-3639.2009.00352.x – volume: 10 start-page: R128 year: 2009 ident: CR29 article-title: Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays publication-title: Genome Biol doi: 10.1186/gb-2009-10-11-r128 – volume: 35 start-page: 679 year: 1976 end-page: 684 ident: CR16 article-title: Sarcoma arising in oligodendroglioma of the brain publication-title: J Neuropathol Exp Neurol doi: 10.1097/00005072-197611000-00005 – volume: 5 start-page: 18 year: 2017 ident: CR2 article-title: Genetic and epigenetic stability of oligodendrogliomas at recurrence publication-title: Acta Neuropathol Commun doi: 10.1186/s40478-017-0422-z – volume: 139 start-page: 603 year: 2020 end-page: 608 ident: CR8 article-title: cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas publication-title: Acta Neuropathol doi: 10.1007/s00401-020-02127-9 – volume: 134 start-page: 705 year: 2017 end-page: 714 ident: CR26 article-title: Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome publication-title: Acta Neuropathol doi: 10.1007/s00401-017-1752-4 – volume: 555 start-page: 469 year: 2018 end-page: 474 ident: CR11 article-title: DNA methylation-based classification of central nervous system tumours publication-title: Nature doi: 10.1038/nature26000 – volume: 138 start-page: 331 year: 2019 end-page: 334 ident: CR18 article-title: Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas publication-title: Acta Neuropathol doi: 10.1007/s00401-019-02025-9 – volume: 127 start-page: 565 year: 2014 end-page: 572 ident: CR32 article-title: Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms publication-title: Acta Neuropathol doi: 10.1007/s00401-014-1246-6 – volume: 26 start-page: 1367 year: 2008 end-page: 1372 ident: CR14 article-title: MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification publication-title: Nat Biotechnol doi: 10.1038/nbt.1511 – volume: 162 start-page: 3019 year: 2020 end-page: 3024 ident: CR25 article-title: Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report publication-title: Acta Neurochir (Wien) doi: 10.1007/s00701-020-04514-3 – volume: 31 start-page: 351 year: 2007 end-page: 362 ident: CR34 article-title: Gliosarcoma arising in oligodendroglial tumors (“oligosarcoma”): a clinicopathologic study publication-title: Am J Surg Pathol doi: 10.1097/01.pas.0000213378.94547.ae – volume: 576 start-page: 112 year: 2019 end-page: 120 ident: CR7 article-title: Longitudinal molecular trajectories of diffuse glioma in adults publication-title: Nature doi: 10.1038/s41586-019-1775-1 – volume: 124 start-page: 547 year: 2012 end-page: 560 ident: CR5 article-title: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status publication-title: Acta Neuropathol doi: 10.1007/s00401-012-1016-2 – year: 2019 ident: CR46 article-title: Gliosarcoma is driven by alterations in PI3K/Akt, RAS/MAPK pathways and characterized by collagen gene expression signature publication-title: Cancers (Basel) doi: 10.3390/cancers11030284 – volume: 33 start-page: 255 year: 2016 end-page: 260 ident: CR38 article-title: Sarcoma-like tumor originating from oligodendroglioma publication-title: Brain Tumor Pathol doi: 10.1007/s10014-016-0268-2 – volume: 21 start-page: 1519 year: 2019 end-page: 1528 ident: CR4 article-title: CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas publication-title: Neuro-Oncol doi: 10.1093/neuonc/noz124 – volume: 140 start-page: 569 year: 2020 end-page: 581 ident: CR6 article-title: Infratentorial IDH-mutant astrocytoma is a distinct subtype publication-title: Acta Neuropathol doi: 10.1007/s00401-020-02194-y – volume: 42 start-page: 2753 year: 1978 end-page: 2758 ident: CR27 article-title: Sarcoma arising in oligodendroglioma of the brain: a case with intramedullary and subarachnoid spinal metastases publication-title: Cancer doi: 10.1002/1097-0142(197812)42:6<2753::aid-cncr2820420634>3.0.co;2-k – volume: 208 start-page: 750 year: 2012 end-page: 755 ident: CR42 article-title: Sarcomatous evolution of oligodendroglioma (“oligosarcoma”): confirmatory report of an uncommon pattern of malignant progression in oligodendroglial tumors publication-title: Pathol Res Pract doi: 10.1016/j.prp.2012.09.009 – volume: 374 start-page: 1344 year: 2016 ident: 2395_CR10 publication-title: N Engl J Med doi: 10.1056/NEJMoa1500925 – volume: 140 start-page: 569 year: 2020 ident: 2395_CR6 publication-title: Acta Neuropathol doi: 10.1007/s00401-020-02194-y – ident: 2395_CR23 doi: 10.1093/neuonc/noab106 – volume: 33 start-page: 255 year: 2016 ident: 2395_CR38 publication-title: Brain Tumor Pathol doi: 10.1007/s10014-016-0268-2 – volume: 32 start-page: 165 year: 2013 ident: 2395_CR19 publication-title: Clin Neuropathol doi: 10.5414/NP300577 – volume: 134 start-page: 705 year: 2017 ident: 2395_CR26 publication-title: Acta Neuropathol doi: 10.1007/s00401-017-1752-4 – volume: 5 start-page: 18 year: 2017 ident: 2395_CR2 publication-title: Acta Neuropathol Commun doi: 10.1186/s40478-017-0422-z – volume: 576 start-page: 112 year: 2019 ident: 2395_CR7 publication-title: Nature doi: 10.1038/s41586-019-1775-1 – volume: 139 start-page: 603 year: 2020 ident: 2395_CR8 publication-title: Acta Neuropathol doi: 10.1007/s00401-020-02127-9 – volume: 139 start-page: 211 year: 2020 ident: 2395_CR17 publication-title: Acta Neuropathol doi: 10.1007/s00401-019-02096-8 – volume: 31 start-page: 344 year: 2013 ident: 2395_CR43 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.43.2229 – volume: 555 start-page: 469 year: 2018 ident: 2395_CR11 publication-title: Nature doi: 10.1038/nature26000 – volume: 42 start-page: 2753 year: 1978 ident: 2395_CR27 publication-title: Cancer doi: 10.1002/1097-0142(197812)42:6<2753::aid-cncr2820420634>3.0.co;2-k – volume: 20 start-page: 245 year: 2010 ident: 2395_CR12 publication-title: Brain Pathol doi: 10.1111/j.1750-3639.2009.00352.x – volume: 138 start-page: 331 year: 2019 ident: 2395_CR18 publication-title: Acta Neuropathol doi: 10.1007/s00401-019-02025-9 – volume: 68 start-page: 567 year: 2018 ident: 2395_CR41 publication-title: Pathol Int doi: 10.1111/pin.12723 – volume: 208 start-page: 750 year: 2012 ident: 2395_CR42 publication-title: Pathol Res Pract doi: 10.1016/j.prp.2012.09.009 – volume: 75 start-page: 501 year: 1983 ident: 2395_CR1 publication-title: Pathologica – ident: 2395_CR35 – volume: 162 start-page: 3019 year: 2020 ident: 2395_CR25 publication-title: Acta Neurochir (Wien) doi: 10.1007/s00701-020-04514-3 – volume: 155 start-page: 462 year: 2013 ident: 2395_CR9 publication-title: Cell doi: 10.1016/j.cell.2013.09.034 – volume: 26 start-page: 1367 year: 2008 ident: 2395_CR14 publication-title: Nat Biotechnol doi: 10.1038/nbt.1511 – volume: 31 start-page: 351 year: 2007 ident: 2395_CR34 publication-title: Am J Surg Pathol doi: 10.1097/01.pas.0000213378.94547.ae – volume: 128 start-page: 551 year: 2014 ident: 2395_CR36 publication-title: Acta Neuropathol doi: 10.1007/s00401-014-1326-7 – volume: 35 start-page: 2394 year: 2017 ident: 2395_CR44 publication-title: J Clin Oncol doi: 10.1200/JCO.2017.72.6737 – volume: 131 start-page: 903 year: 2016 ident: 2395_CR37 publication-title: Acta Neuropathol doi: 10.1007/s00401-015-1519-8 – volume: 29 start-page: 783 year: 2016 ident: 2395_CR47 publication-title: Cancer Cell doi: 10.1016/j.ccell.2016.05.005 – volume: 15 start-page: 1244 year: 2013 ident: 2395_CR31 publication-title: Neuro Oncol doi: 10.1093/neuonc/not092 – volume: 74 start-page: 442 year: 2015 ident: 2395_CR30 publication-title: J Neuropathol Exp Neurol doi: 10.1097/NEN.0000000000000188 – volume: 27 start-page: 1553 year: 2021 ident: 2395_CR45 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-20-0018 – volume: 127 start-page: 565 year: 2014 ident: 2395_CR32 publication-title: Acta Neuropathol doi: 10.1007/s00401-014-1246-6 – volume: 124 start-page: 547 year: 2012 ident: 2395_CR5 publication-title: Acta Neuropathol doi: 10.1007/s00401-012-1016-2 – year: 2019 ident: 2395_CR13 publication-title: Neuro Oncol doi: 10.1093/neuonc/noz098 – volume: 141 start-page: 85 year: 2021 ident: 2395_CR40 publication-title: Acta Neuropathol doi: 10.1007/s00401-020-02243-6 – volume: 35 start-page: 679 year: 1976 ident: 2395_CR16 publication-title: J Neuropathol Exp Neurol doi: 10.1097/00005072-197611000-00005 – volume: 129 start-page: 133 year: 2015 ident: 2395_CR33 publication-title: Acta Neuropathol doi: 10.1007/s00401-014-1370-3 – volume: 20 start-page: 66 year: 2018 ident: 2395_CR3 publication-title: Neuro Oncol doi: 10.1093/neuonc/nox132 – volume: 135 start-page: 955 year: 2018 ident: 2395_CR21 publication-title: Acta Neuropathol doi: 10.1007/s00401-018-1844-9 – volume: 21 start-page: 669 year: 2019 ident: 2395_CR24 publication-title: Neuro Oncol doi: 10.1093/neuonc/noz016 – year: 2020 ident: 2395_CR39 publication-title: Acta Neuropathol doi: 10.1007/s00401-020-02243-6 – volume: 19 start-page: 480 year: 2020 ident: 2395_CR15 publication-title: Nat Rev Drug Discov doi: 10.1038/s41573-020-0070-z – volume: 139 start-page: 597 year: 2020 ident: 2395_CR28 publication-title: Acta Neuropathol doi: 10.1007/s00401-019-02123-8 – volume: 21 start-page: 1519 year: 2019 ident: 2395_CR4 publication-title: Neuro-Oncol doi: 10.1093/neuonc/noz124 – volume: 10 start-page: R128 year: 2009 ident: 2395_CR29 publication-title: Genome Biol doi: 10.1186/gb-2009-10-11-r128 – year: 2019 ident: 2395_CR46 publication-title: Cancers (Basel) doi: 10.3390/cancers11030284 – volume: 9 start-page: 19704 year: 2019 ident: 2395_CR20 publication-title: Sci Rep doi: 10.1038/s41598-019-56247-8 – volume: 46 start-page: 1227 year: 2014 ident: 2395_CR22 publication-title: Nat Genet doi: 10.1038/ng.3095 |
| SSID | ssj0012745 |
| Score | 2.518466 |
| Snippet | Oligodendrogliomas are defined at the molecular level by the presence of an IDH mutation and codeletion of chromosomal arms 1p and 19q. In the past, case... |
| SourceID | pubmedcentral hal proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 263 |
| SubjectTerms | Adult Aged Brain cancer Brain Neoplasms - genetics Brain Neoplasms - pathology Case reports Copy number DNA methylation Epigenetic inheritance Epigenetics Ethylenediaminetetraacetic acid Female Glioma Gliomas Humans Isocitrate Dehydrogenase - genetics Life Sciences Male Medical colleges Medicine Medicine & Public Health Methylation Middle Aged Mutants Mutation Neurosciences Olig2 protein Oligodendroglioma - genetics Oligodendroglioma - pathology Original Paper Pathology Patients Proteomics Sarcoma - genetics Sarcoma - pathology Smooth muscle Tumor cells Tumor proteins Tumors Yes-associated protein |
| SummonAdditionalLinks | – databaseName: SpringerLINK - Czech Republic Consortium dbid: AGYKE link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9NAEB7RVkJcyrsYCjIIiQN1ZXtf3mMELeF9IVI5rfbltqJ1UJNwyK9n1l4buQWkRooUZ8f7nJmd0c58C_DSFMLrivvM1iXJqCE0M5Y49Hm0LMvaUq3bKN8vfDqjH47YUUwKW_TR7v2RZKuph2S3wG_o-pbhSyTL1huwxdBBQXHcmrz7_vFgOD1AT6u7uQDpOXJsTJb5ey2jDSmq5Y2TEBV51eS8Gjl56fi03ZUOb8OsH08XjPJjf7U0-3Z9CerxugO-A9vRTE0nHV_dhRu-uQc3P8eD-PvAvp6dHs8XKCUhvmgvff92mp2vwo3Eqb7wqQuao7H40LhUH7c-ParVBzA7PPj2ZprFGxgyi47VMhOeGCF4jgOWhXRO5tyUQluNG5-WzlTGM4keibOOot1FeK4rVxYWP4wZX5GHsNnMG_8IUiOJJ2VNrOE1xR_akhJF3jhJmatzk0DRL4OyEZ483JJxpgZg5XY-FM6HaudDrRN4PbzzswPn-C_1q7C6Kkgu1mx1TEDA_gUMLDXhFdpOnDOWwO6IEiXOjopfIH8MLQaA7unkkwr_hTbRZJa_CqyjZx8V1cJCBfj7SqLNlCfwfCgO1YdQt8bPVy0NowLtYJrATsdtQ1MB3V-gDCUgRnw46su4pDk9aUHDK4GOZiES2OuZ7U-3_j1nj69H_gRulSE9pI1q34XN5cXKP0WjbWmeRRn9DXmLNbg priority: 102 providerName: Springer Nature |
| Title | Oligosarcomas, IDH-mutant are distinct and aggressive |
| URI | https://link.springer.com/article/10.1007/s00401-021-02395-z https://www.ncbi.nlm.nih.gov/pubmed/34967922 https://www.proquest.com/docview/2617894150 https://www.proquest.com/docview/2615475114 https://hal.univ-lille.fr/hal-04019239 https://pubmed.ncbi.nlm.nih.gov/PMC8742817 |
| Volume | 143 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELfYJiFeEN8ExhQQEg8sIrETO35CaWkpXwUhKpWnyF_ZJo10rC0P--u5c91MYWKRmrSxazvn39l38fmOkJc6E06V3CWmoSzJNcsTbZgFnUdJShuTK-WtfKd8Mss_zot5eOG2DGaV2zHRD9R2YfAd-Rv0HF5KmG7St2e_E4wahaurIYTGDtnLQBLB0A1i3ilcGWhcmwgGoDJzQG7YNOO3ziF6QZGm-GGySC56E1MYnneO0Tryquh51YLyn2VUPzuN75DbQayMqw0O7pIbrr1Hbn4JC-f3SfH19ORosQRUoz3QYfzh3ST5tcYIwrE6d7FFTm8N_GhtrI68Dg7D4AMyG49-DCdJiJiQGFCEVolwTAvBU2iYzKS1MuWaCmUUTFRKWl1qV0jQIKyxOchJjKeqtDQzcBSFdiV7SHbbResek1hL5hhtmNG8yeGLMowCi2or88I2qY5ItiVXbYI7cYxqcVp3jpA9iWsgce1JXF9E5HX3n7ONM41rc7_CXqiR06Bko8KGAWgf-qyqK16CrMN5UURkv5cTOMT0kl9AP3Y1okPtSfW5xntYJ4i48k8GZWy7uQ5svKwvQReR510yFo-maa1brH2eIhcgt-YRebRBRVcVeuMXgPmIiB5eem3pp7Qnx97JdylAMcxERA63yLps1v9p9uT6p3hKblHcvuGtzvfJ7up87Z6BULXSB55zDsheNR4Mpnh9__PTCK6D0fTbd0gd8iGcZ7T6CyvMIZg |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED9tQwJeEN8EBgQE4oFFNHYSxw8IVYypZd142aS-ef7qNmmkY21B7I_ib-TOTTKFib2tUqW2dm33fHe-X30fAG9MKrwuC5_YCeNJZniWGMsdYh4tGZvYTOvg5btbDPazr-N8vAJ_mlgYcqtsdGJQ1G5q6T_yD5Q5vJR43PQ-nf5IqGoU3a42JTSWbLHtf_9CyDb7ONzE_X3L2NaXvc-DpK4qkFgEC_NEeG6EKHreWZlK52SvMExoq1GZa-lMaXwu0cp21mVoS_Cip0vHUouPPDe-5DjuKtzI6IoR5UeMW4CXIsJbVkxAiF6gpNRBOiFUj6QFgTujJ5d5ct45COvjYPWIvDEvm7qXPTb_ubYNp-HWXbhTm7Fxf8l392DFV_fh5k59Uf8A8m8nx4fTGZKL_I824uHmIPm-oIrFsT7zsSPNUll8U7lYHwbMj2r3IexfCy0fwVo1rfwTiI3knrMJt6aYZPhCW85QJRgns9xNeiaCtCGXsnX6cqqicaLaxMuBxApJrAKJ1XkE79vvnC6Td1zZ-x3tgiLJxpGtrgMUcH2UI0v1ixJtq6LI8wjWOz1RIm2n-TXuYzsjJfAe9EeKPqM50aSWP1Mco9lmVauNmbpg8ghetc00PLnCVX66CH3yTKCdnEXweMkV7VSU_V-gjEUgOvzSWUu3pTo-CknFS4FANBURbDScdbGs_9Ps6dW_4iXcGuztjNRouLv9DG4zCh0JHu_rsDY_W_jnaNDNzYsgRTEcXLfY_gUOiFkH |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw9GgXaeIFcScwICAQDyxaEidx_DChQle1bJQJMWlvnm_ZJo10rC2IfSJfxbHrZAoTe1ukSEns2M6xzy0-F4DXMqFGlIWJVJWSKJMki6QiGnUewdK0UpkQzsp3XAz3s08H-cES_Gl8YaxZZUMTHaHWE2X_kW_ayOElQ3YTb1beLGKvP3h_9iOyGaTsTmuTTkP4NAt6y4Ub804eO-b3L1TnplujPs79mzQdbH_7OIx8xoFIoSIxi6ghktIiNlqxhGnN4kKmVCiBhF4wLUtpcoYSuFY6QzmDFLEodZooPPJcmpJgu8uwSpHroyK4-mF7vPe13dNA_W-RTwEV-ALxyLvwOEc-i0uo1qf2JCyPLjps0jOL5WNrq3lVEL5qz_nPpq7jlYM7cNsLuWFvsSrvwpKp78HaZ7-Nfx_yL6cnR5MpAsxaJ22Eo_4w-j63-YxDcW5CbelOrfCm1qE4cn8EkCg_gP0bgeZDWKkntXkMoWTEkLQiShZVhhdCkRQJhtQsy3UVywCSBlxc-eDmNsfGKW_DMjsQcwQxdyDmFwG8a985W4T2uLb2WzsL3OI9tqyEd1_A8dkIWrxXlCh5FUWeB7DeqYn4qjrFr3Ae2x5teO9hb5fbZ7ZPFLjZzwTbaKaZe6Iy5ZcoEMDLttg2bw3lajOZuzp5RlGKzgJ4tFgVbVc2NwBFDAyAdtZLZyzdkvrk2IUcLymqqQkNYKNZWZfD-j_Mnlz_FS9gDVGY747GO0_hVmr9Spw5_DqszM7n5hlKezP53KNRCIc3jbl_AedTY-I |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oligosarcomas%2C+IDH-mutant+are+distinct+and+aggressive&rft.jtitle=Acta+neuropathologica&rft.au=Suwala%2C+Abigail+K.&rft.au=Felix%2C+Marius&rft.au=Friedel%2C+Dennis&rft.au=Stichel%2C+Damian&rft.date=2022-02-01&rft.issn=0001-6322&rft.eissn=1432-0533&rft.volume=143&rft.issue=2&rft.spage=263&rft.epage=281&rft_id=info:doi/10.1007%2Fs00401-021-02395-z&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s00401_021_02395_z |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0001-6322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0001-6322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0001-6322&client=summon |